| 发明名称 |
Treatment of PD-L1-Negative Melanoma Using an Anti-PD-1 Antibody and an Anti-CTLA-4 Antibody |
| 摘要 |
The invention provides a method of treating a melanoma comprising (i) identifying a patient having a PD-L1-negative melanoma and (ii) administering to the patient a combination of an anti-PD-1 antibody or an antigen-binding portion thereof and an anti-CTLA-4 antibody or an antigen-binding portion thereof. The methods of the invention can extend progression-free survival for over 8 months and/or reduces the tumor size at least about 10%, about 20%, about 30%, about 40%, or about 50% compared to the tumor size prior to the administration. |
| 申请公布号 |
US2016340428(A1) |
申请公布日期 |
2016.11.24 |
| 申请号 |
US201615141769 |
申请日期 |
2016.04.28 |
| 申请人 |
Bristol-Myers Squibb Company |
发明人 |
YANG Arvin |
| 分类号 |
C07K16/28;G01N33/577;G01N33/574;A61K45/06;A61K39/395 |
主分类号 |
C07K16/28 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A method for treating a melanoma tumor in a subject in need thereof comprising:
identifying a patient having a PD-L1-negative melanoma tumor; and (ii) administering to the patient:
(a) an anti-PD-1 antibody or an antigen-binding portion thereof that binds specifically to a human PD-1; and(b) an anti-CTLA-4 antibody or an antigen-binding portion thereof that binds specifically to a human CTLA-4. |
| 地址 |
Princeton NJ US |
